We are continuing to work with and deliver for our partners during the COVID-19 pandemic. Read our full response for more details.

Accelerating innovation in viral vector processing

Develop, optimise and scale-up your viral vector project with our Biotherapeutics capabilities

Pharmaceutical label production

We are a leading independent technology innovation centre and a founding member of the UK Government’s High Value Manufacturing Catapult. Established in 2004, our teams tirelessly apply their many years of experience to ensure that every great invention gets the best opportunity to become a successfully marketed product or process.

We help companies to develop, prove, and scale-up the next generation of biologic products and processes and provide our partners with access to the following capabilities:

  • Access to bioprocess development and scale-up experts.

  • End-to-end workflow, from small scale to large scale manufacturing.

  • Experience with a range of AAV serotypes and lentiviral vectors.

  • Access to a diverse range of equipment and expertise.

  • Tech transfer to a client’s manufacturing facility or CMO.

  • Expertise in formulation, cryopreservation development, forced degradation and stability studies.

  • Experience in helping clients to reduce batch-batch variability and improve product quality and quantity.

Our track record of innovation

We have worked on a number of viral vector projects with multiple partners from SMEs to large corporates.

News

Accelerating Gene Therapy with GE Healthcare and Cobra Biologics

Read more 
News

CPI Supports Innovate UK-Funded AAV Gene Therapy Project

Read more 

Innovation Insights

Read what our experts have to say on viral vectors.

Using viruses to fight disease

Discover how modified viruses can help prevent and cure dangerous illnesses. 
Read more 

The potential of gene therapy

Understanding the potential of gene therapy and the processes involved in the manufacture of viral vectors. 
Read more 

Industry challenges

We know current methods of viral vector manufacture are highly inefficient which is putting a strain on drug developers and manufacturers alike. 

  • Upstream titer is low and inconsistent
  • Poor scalability for adherent processes: 2D for process development to 3D for production
  • Difficulties in process adaption from adherent to suspension
  • Downstream recovery is low
  • Analysis of yield and quality is hampered by limited analytical methods
  • High cost of goods

Additionally, when we consider the manufacturing inefficiencies associated with viral vector manufacture such as spoilage, batch failures and QC sampling, organisations are needing to produce on average double the amount they need to accommodate the losses which is time consuming and costly.

Our viral vector capabilities

CPI can help you accelerate viral vector development towards in-human trials and enhance product manufacturability by improving process yield and reducing process variability by generating a robust, scalable and fully transferable process.

<p>Accelerate process development.</p>

Accelerate process development.

<p>Improve process yield.</p>

Improve process yield.

<p>Reduce process variability.</p>

Reduce process variability.

<p>Produce transferable processes.</p>

Produce transferable processes.

<p>Improve process economics and scalability.</p>

Improve process economics and scalability.

<p>Consultancy.</p>

Consultancy.

Cell and Gene Therapy Catapult

A collaborative approach

CPI works closely with the Cell and Gene Therapy Catapult who bring a breadth of knowledge and experience in the area of viral vector processing. They offer:

  • Access to 200+ cell and gene therapy experts
  • MHRA-licensed GMP manufacturing facility
  • Commercial readiness expert support
  • Advanced Therapy Treatment Centre Network

Let’s innovate together

Contact Us